Basit öğe kaydını göster

Serum IL-17 levels can be diagnostic for gastric cancer.

dc.contributor.authorSerimez, Murat
dc.contributor.authorKarabulut, Senem
dc.contributor.authorAfsar, Cigdem Usul
dc.contributor.authorKarabulut, Mehmet
dc.date.accessioned2021-03-02T20:33:57Z
dc.date.available2021-03-02T20:33:57Z
dc.date.issued2019
dc.identifier.citationKarabulut M., Afsar C. U. , Serimez M., Karabulut S., "Serum IL-17 levels can be diagnostic for gastric cancer.", Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.24, sa.4, ss.1601-1609, 2019
dc.identifier.issn1107-0625
dc.identifier.othervv_1032021
dc.identifier.otherav_02a2d905-f75c-4c4d-9dc0-81c17b18f5f3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/7720
dc.description.abstractPurpose: Gastric cancer (GC) is one of the most common malignancies worldwide. Although it has been strongly associated with immunopathology, IL-17 also has an important role in host defense so this makes it more important in GC, which is a microorganism-related cancer. The aim of this study was to determine the clinical significance of the serum levels of IL-17 in GC patients.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleSerum IL-17 levels can be diagnostic for gastric cancer.
dc.typeMakale
dc.relation.journalJournal of B.U.ON. : official journal of the Balkan Union of Oncology
dc.contributor.departmentBakirkoy Dr. Sadi Konuk Research & Training Hospital , ,
dc.identifier.volume24
dc.identifier.issue4
dc.identifier.startpage1601
dc.identifier.endpage1609
dc.contributor.firstauthorID265878


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster